in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including the retirement of Biogen Idec’s CEO and appointments at Dishman and Noven.
James Mullen, president and CEO of Biogen Idec, is to retire from his position effective June 8, 2010. Mullen has been at Biogen for more than 20 years and oversaw the merger with Idec in 2003. Biogen Idec has begun searching for Mullen’s successor.
Dishman has appointed Chris Oates as its chief operating officer, giving him responsibility for operations in India and China. Oates has more than 20 years experience in the pharma industry at companies including Avecia Pharmaceuticals and Uquifa Mexico.
Mark Bagarazzi has been appointed chief medical officer at Inovio Biomedical. Bagarazzi joins in Inovio from Merck & Co, where he was director of worldwide regulatory affairs for vaccines and biologics.
Noven Pharmaceuticals has appointed Andrew Panagy as vice president (VP), marketing and sales and Natalie Estrella as VP, human resources.
Panagy has more than 30 years experience in pharma and biotech, most recently at Wyeth. He has also held positions at Pfizer, Neuromedical Systems and MEDED Healthcare. Estrella spent 14 years at Johnson & Johnson companies in her 30 year career.
Stephen Yoder has been appointed as CEO of Pieris AG with immediate effect. Yoder replaces interim-CEO and co-founder Claus Schalper who will remain chief financial officer. Before joining Pieris Yoder worked at MorphoSys where he was involved in deals with Novartis and Daiichi-Sankyo.
BioVex has named Tim Hanke as VP commercial operations. Hanke has previously worked at Genta, Chiron Biopharmaceuticals and Berlex Laboratories.